AlphAIAlphAI — Financial news for AI agents
MarketBeatMAR 154 min read$ORIC

Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC recently reduced its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 14.2% in the third quarter, selling 180,957 shares and retaining over 1 million shares valued at approximately $13.17 million. This move comes as company insiders have also been net sellers, with CEO Jacob Chacko and another insider selling shares totaling over $1.20 million in the past three months. Despite insider selling, analysts maintain a "Moderate Buy" consensus and a price target of $20.20 for ORIC, which is currently trading around $11.90.

Original reporting
MarketBeat · MarketBeat
Published Mar 15, 2026, 7:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 15, 2026, 9:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC — source image
Source · MarketBeat
Decision brief

The 30-second read

$ORICNeutralMed
01

Why it matters

While insider and institutional selling can signal caution, the overall analyst sentiment remains moderately bullish, with a price target of $20.20 compared to the current trading price around $11.90.

02

Market read

The insider activity and stake reduction are noteworthy but do not definitively predict a trend; traders should watch for further insider or institutional moves.

03

What to watch

Potential upcoming catalysts such as clinical trial results or partnership announcements could offset insider activity concerns

Relevance 6/10Timing: short to medium term

Background

ArrowMark Colorado Holdings LLC reduced its stake in ORIC by 14.2% in Q3, selling approximately 180,957 shares, while insiders including the CEO sold over $1.2 million worth of shares in the past three months.

Company-level read

Ticker impact

$ORICNeutralMedium confidence
Context

Recent insider activity and institutional stake reduction

Expected impact

Potential short-term price decline followed by stabilization

Evidence & confidence

While insider selling and stake reduction may indicate caution, analyst ratings and price targets support a moderate bullish outlook. Lack of significant negative news limits downside risk.

Market effects

Sector

Possible minor impact on biotech and life sciences sector sentiment

Regional

Limited regional impact due to company-specific news

Global

Low, as news is company-specific and insider activity

Counterpoint

What could challenge this read

Insider selling may be routine and not indicative of future performance; the company’s fundamentals and analyst support suggest long-term growth potential

Key entities

  • Institutional Investor
    ArrowMark Colorado Holdings LLC

    A hedge fund that reduced its stake in ORIC.

  • CEO
    Jacob Chacko

    Insider who sold shares totaling over $600,000 in recent months.

Read at source← All news

Related articles

OCT 5
$ORICLow

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

ORIC Pharmaceuticals (ORIC) partnered with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Cancer Research UK will fund and execute early clinical trials, while ORIC retains an option to reacquire rights post-Phase 1/2 data. ORIC-259 targets CIP2A, a protein linked to cancer progression, with promising preclinical data showing antitumor activity in HRD cancers.

globenewswire.com2 min
SEP 15
$ORICMedAI 8/10

ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch

ORIC Pharmaceuticals (ORIC) reported Q2 results, launching a Phase 3 trial for its prostate cancer drug rinzimetostat. The company has $387.6M in cash, funding operations into 2028. R&D costs rose to $36.3M, widening net loss to $41.5M. ORIC also advanced its lung cancer program enozertinib, with data expected later this year.

yahoo.com2 min
AUG 3
$ORICMed

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Ba

SEC EDGAR 8-K6 min
OCT 9
$BHVNMedAI 8/10

Biohaven partners with Ono in $100m IgG degrader deal

Biohaven has partnered with Ono Pharmaceutical in a $100m deal for its MoDE IgG degrader portfolio, including BHV-1300, BHV-1310, and BHV-1320. Ono gains exclusive rights in ASEAN, Taiwan, South Korea, and Japan, with an $80m upfront payment and a $20m milestone. Biohaven retains global rights and is eligible for 20% royalties. BHV-1300 is in Phase III trials for Graves' disease, showing up to 87% IgG reduction. According to Biohaven, Ono will help bring the technology to Asian markets.

finance.yahoo.com2 min